Monoclonal antibodies against doxorubicin

A. Balsari, R. Alzani, D. Parrello, D. Morelli, E. Tagliabue, L. Gianni, A. M. Isetta, S. Menard, M. I. Colnaghi, M. Ghione

Research output: Contribution to journalArticlepeer-review


Hybridomas which secrete monoclonal antibodies (MAbs) reacting with doxorubicin (DXR), a widely used anthracycline cytotoxic antibiotic, have been obtained by fusing NSO/P3 mouse myeloma cells with spleen cells from BALB/c mice immunized with DXR-BSA conjugate. The best producer among the several clones obtained was expanded and the secreted MAb (MAD2) purified and characterized. MAD2 cross-reacts to varying degrees with anthracycline compounds such as some DXR analogues and derivatives, but does not recognize anthracene and anthraquinone structures, with the exception of weakly reacting Mitoxantrone. MAD2 and the panel of MAbs which are at present being purified may become a tool for studying the relevance of different domains of the anthracyclin molecule in terms of biologic activity.

Original languageEnglish
Pages (from-to)798-802
Number of pages5
JournalInternational Journal of Cancer
Issue number5
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Monoclonal antibodies against doxorubicin'. Together they form a unique fingerprint.

Cite this